---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-010067"
form_type: "8-K"
ticker: "DNA"
cik: "0001830214"
company_name: "Ginkgo Bioworks Holdings, Inc."
filed_at: "2022-05-16T23:59:59+00:00"
generated_at: "2026-06-25T15:31:32.965013+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Ginkgo Q1 revenue $168M (+282% YoY); raises FY22 total revenue guidance to $375-390M

## Summary
- Total revenue $168M (+282% YoY); Foundry revenue $21M (-5% YoY); Biosecurity revenue $147M.
- Loss from operations $(675)M incl. $659M stock comp; Adj. EBITDA $(2)M improved from $(51)M.
- Added 11 new Cell Programs in Q1; FY22 target of 60 new programs unchanged.
- Raised FY22 total revenue guidance to $375-390M from $325-340M; Foundry guidance unchanged.
- Announced plans to acquire Bayer's West Sacramento ag biologics site and flagship collaboration.

## SEC filing metadata
- accession: 0000950170-22-010067
- form_type: 8-K
- ticker: DNA
- cik: 0001830214
- company_name: Ginkgo Bioworks Holdings, Inc.
- filed_at: 2022-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1830214/000095017022010067/0000950170-22-010067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1830214/000095017022010067/dna-20220516.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-010067
- JSON: https://secwatch.observer/filing/0000950170-22-010067.json
- Plain text: https://secwatch.observer/filing/0000950170-22-010067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.